<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04643340</url>
  </required_header>
  <id_info>
    <org_study_id>2017-00483</org_study_id>
    <nct_id>NCT04643340</nct_id>
  </id_info>
  <brief_title>Imaging During Subliminal Perception</brief_title>
  <official_title>Functional Imaging During Subliminal Perception</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subliminal perception of visual stimuli can be studied with functional brain imaging, e.g.&#xD;
      with functional magnetic resonance imaging (fMRI). However, it is unclear how subliminal&#xD;
      perception affects connectivity in the brain.&#xD;
&#xD;
      Further, it is not known if real-time (rt) fMRI neurofeedback of brain areas involved in&#xD;
      subliminal perception can lead to supra-threshold perception.&#xD;
&#xD;
      For attention tasks, the investigators hypothesize that functional connectivity strength is&#xD;
      mediated by the insular cortex during both supra-threshold and subliminal perception.&#xD;
&#xD;
      Additionally, the investigators hypothesize that rt-fMRI neurofeedback training should alter&#xD;
      neuronal and behavioral responses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this project, using healthy adults, the investigators have 2 aims:&#xD;
&#xD;
        1. Apply electroencephalography (EEG) and fMRI before and after rt-fMRI neurofeedback&#xD;
           during attention tasks to identify brain regions involved in subliminal and supraliminal&#xD;
           perception.&#xD;
&#xD;
        2. Apply functional connectivity analyses during these tasks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>fMRI during supra-threshold and subliminal perception</measure>
    <time_frame>2020 - 2022</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>rt-fMRI activity</measure>
    <time_frame>2020 - 2022</time_frame>
    <description>rt-fMRI activity: fMRI signal changes during repetitive real time fMRI based training</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional connectivity</measure>
    <time_frame>2020 - 2022</time_frame>
    <description>Examination of fMRI signal dependencies (coherence) between brain regions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EEG activity</measure>
    <time_frame>2020 - 2022</time_frame>
    <description>EEG activity: Event related potentials and spectral band power for different trial types</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fMRI task performance</measure>
    <time_frame>2020 - 2022</time_frame>
    <description>Reaction time and accuracy</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>active group 1</arm_group_label>
    <description>This group will train the insular cortex by real-time fMRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>active group 2</arm_group_label>
    <description>This group will train the visual cortex by real-time fMRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham</arm_group_label>
    <description>This group will only train the insula by a particular strategy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>real-time fMRI</intervention_name>
    <description>Brain regions can be trained, i.e. fMRI activity can be actively modulated online by humans, using rt-fMRI (Bruhl, Scherpiet et al. 2014, Bruhl 2015, Emmert, Kopel et al. 2016).</description>
    <arm_group_label>active group 1</arm_group_label>
    <arm_group_label>active group 2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy adults&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adults (&gt; 18 &lt; 80 years), which can read and sign the informed consent form&#xD;
&#xD;
          -  Male and female&#xD;
&#xD;
          -  Right-handed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  metallic items in the body (i.e. eye splinter, MR incompatible implants)&#xD;
&#xD;
          -  pacemaker&#xD;
&#xD;
          -  claustrophobia&#xD;
&#xD;
          -  pregnant participants&#xD;
&#xD;
          -  participants suffering from a degenerative disorder of the Central Nervous System,&#xD;
             such as Stroke, Multiple Sclerosis, Parkinson's Disease, Alzheimer's Disease and&#xD;
             Huntington's Disease and with major psychiatric disorders such as schizophrenia,&#xD;
             depression, or anxiety disorder&#xD;
&#xD;
          -  Drug intake (psychopharmaca)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Michels, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Zürich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lars Michels, PhD</last_name>
    <phone>0041442554965</phone>
    <email>lars.michels@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeanette Popovova, Msc</last_name>
    <phone>0041442555604</phone>
    <email>jeanette.popovova@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Zurich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Michels, PhD</last_name>
      <phone>0041442554965</phone>
      <email>lars.michels@usz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://p3.snf.ch/project-182803</url>
    <description>SNF database</description>
  </link>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2020</study_first_posted>
  <last_update_submitted>November 24, 2020</last_update_submitted>
  <last_update_submitted_qc>November 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>functional MRI</keyword>
  <keyword>subliminal perception</keyword>
  <keyword>EEG</keyword>
  <keyword>neurofeedback</keyword>
  <keyword>attention</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Raw imaging data can be shared with other groups (outside of the USZ), e.g. for replication purpose.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

